DEV Community

Rohan Tech official
Rohan Tech official

Posted on Originally published at rohantechofficial.com

Google DeepMind Launches AlphaGenome 2 — DNA Predictions Now Down to the Single Cell

Google DeepMind Launches AlphaGenome 2 — DNA Predictions Now Down to the Single Cell

A DNA variant doesn't behave the same way in every cell. It might matter in an immune cell and do nothing at all in a skin cell — which is why tissue averages can mislead. Google DeepMind's AlphaGenome 2, launched on November 11, 2026, is built around that problem: instead of predicting what a DNA sequence does across a broad tissue average, it aims at specific cell types and cell states.

From tissue averages to single cells

As reported by SXF Brief and The Neuron on November 12, AlphaGenome 2 moves the prediction down to the level where variants actually act. To learn the differences between cell types, it was trained on more than 107 million individual cell profiles spanning 68 tissues — the same genome, read in dozens of different biological settings.

Why does that granularity matter? A variant tied to an immune condition may only change gene activity inside particular immune cells. Average that across a whole tissue and the signal can wash out entirely. A cell-level model gives researchers a sharper question to take into the lab.

The TenK10K result

On the TenK10K immune-cell dataset, AlphaGenome 2 identified 30% of causal expression variants — the changes that actually drive a gene's activity up or down — against 16% for the original AlphaGenome. Close to double, on the same dataset.

Worth keeping in proportion: 30% also means 70% weren't identified. This is a research instrument getting sharper, not a solved problem, and one immune-cell benchmark can't tell us how it performs everywhere else.

Research only — DeepMind says so plainly

AlphaGenome 2 is available through the AlphaGenome API for non-commercial research only. DeepMind states explicitly that it is not approved for clinical or diagnostic use. So no, doctors can't use it to read a patient's genome today — what it offers, for now, is a stronger tool for the lab work that has to happen long before anything clinical is on the table.

I wrote up the full story, including what the cell-level shift means and where the limits sit, on Rohan Tech Official: Google DeepMind Launches AlphaGenome 2

Top comments (0)